FIELD: biotechnology.
SUBSTANCE: an antibody and fusion protein for use in therapeutic treatment of dogs are presented with specific heavy chain isotypes. The amino acid sequence of the heavy chain mediates the activation of effector functions of the immune system at binding antibodies or fusion protein to the target antigen.
EFFECT: invention can be used for treatment of pathological conditions such as pain, inflammatory conditions and cancer conditions of dogs.
12 cl, 15 dwg, 8 ex
| Title | Year | Author | Number |
|---|---|---|---|
| THERAPEUTIC CANINE IMMUNOGLOBULINS AND METHODS FOR THEIR USE | 2012 |
|
RU2627191C2 |
| ANTIBODIES AGAINST NERVE GROWTH FACTOR AND METHODS FOR THEIR PRODUCTION AND APPLICATION | 2012 |
|
RU2644235C2 |
| ANTIBODIES AGAINST NERVE GROWTH FACTOR AND METHODS FOR THEIR PRODUCTION AND APPLICATION | 2012 |
|
RU2640252C2 |
| ANTIBODIES AGAINST NERVE GROWTH FACTOR AND METHODS FOR THEIR PRODUCTION AND APPLICATION | 2012 |
|
RU2640254C2 |
| ANTIBODY AGAINST PD-L1 | 2017 |
|
RU2744862C2 |
| MONOCLONAL ANTIBODIES AGAINST INTERLEUKIN-31 | 2012 |
|
RU2588462C2 |
| ANTIBODIES TO CANINE PD-1 | 2014 |
|
RU2761663C2 |
| CANINISED MURINE ANTIBODIES TO HUMAN PD-1 | 2014 |
|
RU2676158C1 |
| C5 ANTIBODY AND METHOD FOR PREVENTING AND TREATING COMPLEMENT-RELATED DISEASES | 2014 |
|
RU2663349C2 |
| ANTIBODIES TO CANINE INTERLEUKIN-4 ALPHA RECEPTOR | 2016 |
|
RU2736732C2 |
